Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: A prospective, randomized study

Human Reproduction

Volumn 15, Issue 10, 2000, Pages 2087-2092

  Tira, M B ^a,c   Noyan, V ^a   Yildiz, A ^a   Yildirim, M ^a   Daya, S ^b  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b MCMASTER UNIVERSITY   (Canada)

^c NONE   (Turkey)

Author keywords

Alendronate; Bone mineral density; Hormone replacement therapy; Menopause; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; MINERAL; NORETHISTERONE ACETATE; SEX HORMONE;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS DISEASE; FEMALE; FEMUR NECK; FOLLOW UP; HEADACHE; HORMONE SUBSTITUTION; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MINERAL METABOLISM; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SPINE; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION;

EID: 0033776679     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Individualizing therapy to prevent long term consequences of estrogen deficiency in postmenopausal women
2. HRT and osteoporosis
3. Appendicular bone density and age predict hip fracture in women
4. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
5. Long term estrogen replacement therapy prevents bone loss and fractures
6. Low dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women
7. The effect of postmenopausal estrogen therapy on bone density in elderly women
8. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
9. Estrogens in the prevention of osteoporosis in postmenopausal women
10. The bone-remodelling transitient: Implications for the interpretation of clinical studies of bone mass change
11. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group
12. Alendronate: A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis
13. Hip fracture and the use of estrogens in postmenopausal women: The Framingham study
14. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
15. Estrogen treatment of patients with established postmenopausal osteoporosis
16. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
17. Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines, International Committee for Osteoporosis Clinical Guidelines
18. Estrogen therapy arrests bone loss in elderly women
19. Pharmacological management of osteoporosis in postmenopausal woman; a comparative review
20. Management of postmenopausal osteoporosis
21. Clinical heterogeneity of involutional osteoporosis: Implications of preventive therapy
22. The prevention and treatment of osteoporosis
23. Differential changes in bone mineral density of the appendicular skeleton with aging: Relationship to spinal osteoporosis
24. Combined estrogen and alendronate treatment increases bone density and vertebral strength in osteopenic rats
25. Effect of three years of alendronate treatment in postmenopausal women with osteoporosis
26. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen